Updated Jul 16, 2026
Horn Howard has filed 4 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $1.61M.
Howard Horn is the Chief Financial Officer of Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on developing treatments for rare diseases. He has been involved in multiple SEC filings related to his role at the company.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-06 | RARE | Ultragenyx Pharmaceutical Inc. | S — Open-market sale | 4.7K | $33.13 | $156K |
| 2026-06-01 | RARE | Ultragenyx Pharmaceutical Inc. | S — Open-market sale | 4.7K | $23.77 | $111K |
| 2026-05-04 | RARE | Ultragenyx Pharmaceutical Inc. | S — Open-market sale | 4.7K | $24.90 | $117K |
| 2026-04-20 | RARE | Ultragenyx Pharmaceutical Inc. | A — Grant or award | 34.7K | $0.00 | |
| 2026-04-02 | RARE | Ultragenyx Pharmaceutical Inc. | S — Open-market sale | 4.7K | $20.97 | $98K |
| 2026-03-03 | RARE | Ultragenyx Pharmaceutical Inc. | S — Open-market sale | 1.6K | $22.40 | $37K |
| 2026-03-03 | RARE | Ultragenyx Pharmaceutical Inc. | S — Open-market sale | 3.1K | $22.54 | $70K |
| 2026-03-03 | RARE | Ultragenyx Pharmaceutical Inc. | S — Open-market sale | 5.3K | $22.80 | $121K |
| 2026-03-03 | RARE | Ultragenyx Pharmaceutical Inc. | A — Grant or award | 6.1K | $0.00 | |
| 2026-02-03 | RARE | Ultragenyx Pharmaceutical Inc. | S — Open-market sale | 3.1K | $23.56 | $72K |
| 2026-01-05 | RARE | Ultragenyx Pharmaceutical Inc. | S — Open-market sale | 3.1K | $22.84 | $72K |
| 2025-12-11 | RARE | Ultragenyx Pharmaceutical Inc. | S — Open-market sale | 3.1K | $36.38 | $112K |
| 2025-10-13 | RARE | Ultragenyx Pharmaceutical Inc. | S — Open-market sale | 7.9K | $31.51 | $250K |
| 2024-10-11 | RARE | Ultragenyx Pharmaceutical Inc. | S — Open-market sale | 7.5K | $52.76 | $394K |
Howard Horn is the Chief Financial Officer of Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on developing treatments for rare diseases. He has been involved in multiple SEC filings related to his role at the company.…
4 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 12 open-market sales ($1.61M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Horn Howard profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.